SCHEMBL4883349

SCHEMBL4883349

COC(=O)Nc1cccc([C]=O)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 1/20 0.43
HPGD P15428 4/20 0.42
PLAU P00749 1/20 0.40
ALDH1A1 P00352 4/20 0.40
ALOX15 P16050 2/20 0.40
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
KDM4E B2RXH2 1/20 0.38
KMT2A Q03164 3/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPK1 P28482 2/20 0.37
MEN1 O00255 2/20 0.37
FAAH O00519 1/20 0.37
CYP3A4 P08684 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NLRP3 Q96P20 1/20 0.37
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4882527 0.84 ALDH1A1 (0.55) HPGDALDH1A1HSD17B10LMNAKMT2A
SCHEMBL4883113 0.84 HPGD (0.44) CXCR2HPGDALDH1A1ALOX15KDM4E
SCHEMBL7256914 0.84 HPGD (0.52) HPGDPLAUALDH1A1ALOX15HSD17B10
SCHEMBL4880034 0.83 ALDH1A1 (0.47) CXCR2HPGDALDH1A1ALOX15HSD17B10
SCHEMBL4889784 0.82 HPGD (0.47) HPGDALDH1A1LMNAKMT2AMAPK1
SCHEMBL4889765 0.79 CETP (0.49) CXCR2LMNAKDM4EKMT2AGAA
SCHEMBL4888919 0.79 HPGD (0.44) CXCR2HPGDALDH1A1LMNAKDM4E
SCHEMBL4888916 0.75 SMN1; SMN2 (0.49) CXCR2HPGDALDH1A1LMNAKMT2A
SCHEMBL8652549 0.75 KDM4E (0.56) CXCR2HPGDALDH1A1ALOX15HSD17B10
SCHEMBL4883127 0.74 TSHR (0.62) ALDH1A1ALOX15HSD17B10GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275112-A1 Invention Concerning Aminoadamantane Compounds SCHREINER PETER R 2008-11-06 US claimed
EP-1789380-A1 AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF Justus-Liebig-Universität Giessen (DE) 2007-05-30 EP claimed
WO-2006010362-A1 AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) 2006-02-02 WO claimed
US-20080275112-A1 Invention Concerning Aminoadamantane Compounds SCHREINER PETER R 2008-11-06 US disclosed
EP-1789380-A1 AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF Justus-Liebig-Universität Giessen (DE) 2007-05-30 EP disclosed
WO-2006010362-A1 AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275112-A1 Invention Concerning Aminoadamantane Compounds GABRA5, GABRA1, GABRA4 CXCR2 3787/4885HPGD 2622/4885PLAU 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.